


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1. **(currently amended)** A particle consisting of a solid dispersion, comprising:

(a) a compound of formula



a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof,

wherein

Y is CR<sup>5</sup> or N;

A is CH, CR<sup>4</sup> or N;

n is 0, 1, 2, 3 or 4;

Q is -NR<sup>1</sup>R<sup>2</sup> or when Y is CR<sup>5</sup> then Q may also be hydrogen;

R<sup>1</sup> and R<sup>2</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkyloxy, C<sub>1-12</sub>alkylcarbonyl, C<sub>1-12</sub>alkyloxycarbonyl, aryl, amino, mono- or di(C<sub>1-12</sub>alkyl)amino, mono- or di(C<sub>1-12</sub>alkyl)aminocarbonyl wherein each of the aforementioned C<sub>1-12</sub>alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-6</sub>alkyloxy, carboxyl, C<sub>1-6</sub>alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C<sub>1-6</sub>alkyl)amino, aryl and Het; or R<sup>1</sup> and R<sup>2</sup> taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C<sub>1-12</sub>alkyl)aminoC<sub>1-4</sub>alkylidene;

**Het is an aliphatic or aromatic heterocyclic radical, wherein said aliphatic heterocyclic radical is optionally substituted with an oxo group**

**and wherein said aromatic heterocyclic radical is optionally substituted with hydroxy;**

$R^3$  is hydrogen, aryl,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxycarbonyl,  $C_{1-6}$ alkyl substituted with  $C_{1-6}$ alkyloxycarbonyl;

each  $R^4$  independently is hydroxy, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or when Y is  $CR^5$  then  $R^4$  may also represent  $C_{1-6}$ alkyl substituted with cyano or aminocarbonyl;

$R^5$  is hydrogen or  $C_{1-4}$ alkyl;

L is  $-X^1-R^6$  or  $-X^2-Alk-R^7$ , wherein

$R^6$  and  $R^7$  each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is  $CR^5$  then  $R^6$  and  $R^7$  may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then  $R^6$  and  $R^7$  may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyloxy,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;

$X^1$  and  $X^2$  are each independently  $-NR^3-$ ,  $-NH-NH-$ ,  $-N=N-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

Alk is  $C_{1-4}$ alkanediyl; or

when Y is  $CR^5$  then L may also be selected from  $C_{1-10}$ alkyl,  $C_{3-10}$ alkenyl,  $C_{3-10}$ alkynyl,  $C_{3-7}$ cycloalkyl, or  $C_{1-10}$ alkyl substituted with one or two substituents independently selected from  $C_{3-7}$  cycloalkyl,

indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, aminocarbonyl, C<sub>1-6</sub> alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C<sub>1-6</sub>alkylcarbonyl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, cyano, nitro and trifluoromethyl; and

(b) one or more pharmaceutically acceptable water-soluble polymers.

2. *(previously presented)* A particle according to claim 1, 25 or 26 having a particle size of less than 1500 µm.

3. *(previously presented)* A particle according to claim 1, 25 or 26, wherein said compound (a) is in a non-crystalline phase.

4. *(previously presented)* A particle according to claim 1, 25 or 26, wherein the solid dispersion is in the form of a solid solution comprising said compound (a) and said polymer (b).

5. *(previously presented)* A particle consisting of a solid dispersion, comprising:

(a) a compound selected from the group consisting of

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile

4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino] benzonitrile,

4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile,

4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile,

4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile,

4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile,

4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile, and

4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile; and

(b) one or more pharmaceutically acceptable water-soluble polymers.

6. *(previously presented)* A particle according to claim 1, wherein said compound (a) is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile.

7. *(previously presented)* A particle according to claim 1, 25 or 26, wherein said water-soluble polymer is a polymer that has an apparent viscosity of 1 to 5000 mPa·s when dissolved at 20°C in an aqueous solution at 2% (w/v).

8. *(previously presented)* A particle according to claim 7, wherein the water-soluble polymer is a polymer selected from the group consisting of:

alkylcelluloses,  
hydroxyalkylcelluloses,  
hydroxyalkyl alkylcelluloses,  
carboxyalkylcelluloses,  
alkali metal salts of carboxyalkylcelluloses,  
carboxyalkylalkylcelluloses,  
carboxyalkylcellulose esters,  
starches,  
pectines,

**DOCKET NO.:** JANS-0031 (JAB-1531 US)  
**Application No.:** 10/088,805  
**Office Action Dated:** February 9, 2004

**PATENT**

chitin derivatives,  
di-, oligo- or polysaccharides,  
polyacrylic acids and the salts thereof,  
polymethacrylic acids, the salts and esters thereof, methacrylate copolymers,  
polyvinylalcohol, and  
polyalkylene oxides.

9. *(previously presented)* A particle according to claim 8, wherein said water-soluble polymer is hydroxypropyl methylcellulose.
10. *(previously presented)* A particle according to claim 9, wherein the weight ratio of (a):(b) is in the range of 1:1 to 1:899.
11. *(canceled)*
12. *(previously presented)* A particle according to claim 1, 25 or 26 consisting of a solid solution, comprising:
- (a) two parts by weight of said compound (a); and
  - (b) three parts by weight of hydroxypropyl methylcellulose.
13. *(previously presented)* A particle according to claim 1, 25 or 26, further comprising one or more pharmaceutically acceptable excipients.

Claims 14 to 27 *(canceled)*

28. *(previously presented)* A particle according to claim 4, further comprising a material selected from said compound (a) and said polymer (b);  
wherein said material is dispersed in said solid solution to form a solid dispersion;

**DOCKET NO.:** JANS-0031 (JAB-1531 US)

**PATENT**

**Application No.:** 10/088,805

**Office Action Dated:** February 9, 2004

wherein said compound (a) is in a form selected from amorphous and microcrystalline; and

wherein said polymer (b) is in a form selected from amorphous and microcrystalline.

29. *(cancelled)*